Joline S.W. Lind

826 total citations
20 papers, 656 citations indexed

About

Joline S.W. Lind is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joline S.W. Lind has authored 20 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Joline S.W. Lind's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (4 papers). Joline S.W. Lind is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Research Studies (4 papers). Joline S.W. Lind collaborates with scholars based in Netherlands, United States and Italy. Joline S.W. Lind's co-authors include Egbert F. Smit, Suresh Senan, Pieter E. Postmus, Frank J. Lagerwaard, Anne‐Marie C. Dingemans, Jan G. Zijlstra, Jaap E. Tulleken, Richard J. Honeywell, Elisa Giovannetti and Godefridus J. Peters and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Joline S.W. Lind

20 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joline S.W. Lind Netherlands	14	315	276	184	108	86	20	656
D. Nagel Germany	11	261 0.8×	405 1.5×	228 1.2×	142 1.3×	85 1.0×	24	960
Yasuhito Fujisaka Japan	17	272 0.9×	481 1.7×	247 1.3×	109 1.0×	33 0.4×	51	885
Raimondo Di Liello Italy	13	228 0.7×	357 1.3×	265 1.4×	44 0.4×	31 0.4×	33	738
Seung‐Gu Yeo South Korea	18	247 0.8×	612 2.2×	137 0.7×	22 0.2×	168 2.0×	64	968
Katsuyuki Kuratsukuri Japan	11	285 0.9×	153 0.6×	197 1.1×	48 0.4×	163 1.9×	42	587
Rajendra Pradhan United States	14	121 0.4×	131 0.5×	200 1.1×	56 0.5×	32 0.4×	33	795
Sophie Broutin France	16	96 0.3×	311 1.1×	213 1.2×	180 1.7×	63 0.7×	48	787
Maria Rosa Cappelletti Italy	13	251 0.8×	312 1.1×	213 1.2×	31 0.3×	57 0.7×	32	635
Christopher Toth United States	11	54 0.2×	211 0.8×	229 1.2×	91 0.8×	103 1.2×	15	586
Alan D. Smith United Kingdom	14	361 1.1×	236 0.9×	234 1.3×	51 0.5×	68 0.8×	35	635

Countries citing papers authored by Joline S.W. Lind

Since Specialization

Citations

This map shows the geographic impact of Joline S.W. Lind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joline S.W. Lind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joline S.W. Lind more than expected).

Fields of papers citing papers by Joline S.W. Lind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joline S.W. Lind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joline S.W. Lind. The network helps show where Joline S.W. Lind may publish in the future.

Co-authorship network of co-authors of Joline S.W. Lind

This figure shows the co-authorship network connecting the top 25 collaborators of Joline S.W. Lind. A scholar is included among the top collaborators of Joline S.W. Lind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joline S.W. Lind. Joline S.W. Lind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rovithi, Maria, Joline S.W. Lind, Thang V. Pham, et al.. (2016). Response and toxicity prediction by MALDI‐TOF‐MS serum peptide profiling in patients with non‐small cell lung cancer. PROTEOMICS - CLINICAL APPLICATIONS. 10(7). 743–749. 6 indexed citations

Kuiper, JG, Joline S.W. Lind, Harry J.M. Groen, et al.. (2012). VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. British Journal of Cancer. 107(11). 1820–1825. 34 indexed citations

Giovannetti, Elisa, Mariëtte Labots, Henk Dekker, et al.. (2012). Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. Current Pharmaceutical Design. 19(5). 927–939. 25 indexed citations

Lind, Joline S.W., Suresh Senan, & Egbert F. Smit. (2012). Pulmonary Toxicity After Bevacizumab and Concurrent Thoracic Radiotherapy Observed in a Phase I Study for Inoperable Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(8). e104–e108. 51 indexed citations

Honeywell, Richard J., Elisa Giovannetti, Nienke Losekoot, et al.. (2010). Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. Journal of Chromatography B. 878(15-16). 1059–1068. 83 indexed citations

Lind, Joline S.W., Pieter E. Postmus, & Egbert F. Smit. (2010). Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report. Journal of Thoracic Oncology. 5(4). 554–557. 18 indexed citations

Lind, Joline S.W., Frank J. Lagerwaard, Egbert F. Smit, et al.. (2010). Time for reappraisal of extracranial treatment options?. Cancer. 117(3). 597–605. 15 indexed citations

Smit, Egbert F., Heinrich Röder, Julia Grigorieva, et al.. (2010). 614 The proteomic classifier VeriStrat® identifies advanced non small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib. European Journal of Cancer Supplements. 8(7). 193–193. 2 indexed citations

Lind, Joline S.W., Martijn R. Meijerink, Anne‐Marie C. Dingemans, et al.. (2010). Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. European Radiology. 20(12). 2890–2898. 68 indexed citations

10.

Lind, Joline S.W., Anne‐Marie C. Dingemans, Harry J.M. Groen, et al.. (2010). A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 16(11). 3078–3087. 74 indexed citations

11.

Lind, Joline S.W., Jan G. Zijlstra, Maarten P. van den Berg, et al.. (2009). Cardiac assessment of patients with late stage Duchenne muscular dystrophy. Netherlands Heart Journal. 17(6). 232–237. 20 indexed citations

12.

Lind, Joline S.W., Richard R. de Haas, Henk M.W. Verheul, et al.. (2009). CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. British Journal of Cancer. 102(2). 268–275. 27 indexed citations

13.

Lind, Joline S.W., Pieter E. Postmus, Daniëlle A.M. Heideman, et al.. (2009). Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous Toxicity. Journal of Thoracic Oncology. 4(12). 1585–1586. 18 indexed citations

14.

Lind, Joline S.W., Frank J. Lagerwaard, Egbert F. Smit, & Suresh Senan. (2009). Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 74(5). 1391–1396. 55 indexed citations

15.

Lind, Joline S.W. & Egbert F. Smit. (2009). Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 1(2). 95–107. 9 indexed citations

16.

Lind, Joline S.W., Anne‐Marie C. Dingemans, Harry J.M. Groen, & Egbert F. Smit. (2009). A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8018–8018. 2 indexed citations

17.

Lind, Joline S.W., Egbert F. Smit, Katrien Grünberg, Suresh Senan, & Frank J. Lagerwaard. (2008). Fatal Interstitial Lung Disease After Erlotinib for Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(9). 1050–1053. 21 indexed citations

18.

Lind, Joline S.W., Gerarda J.M. Herder, & Egbert F. Smit. (2008). [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].. PubMed. 152(16). 928–32. 2 indexed citations

19.

Lind, Joline S.W., Frank J. Lagerwaard, Egbert F. Smit, & Suresh Senan. (2008). Whole brain radiotherapy with concurrent erlotinib for brain metastases from non-small cell lung cancer: A phase I study. Journal of Clinical Oncology. 26(15_suppl). 19122–19122. 1 indexed citations

20.

Ligtenberg, Jack J. M., Iwan CC van der Horst, Rob Spanjersberg, et al.. (2006). Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients. Critical Care. 10(5). R135–R135. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact